Contemporary mTOR inhibitor scaffolds to diseases breakdown: A patent review (2015–2021)
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F62690094%3A18470%2F22%3A50019214" target="_blank" >RIV/62690094:18470/22:50019214 - isvavai.cz</a>
Alternative codes found
RIV/00179906:_____/22:10445942
Result on the web
<a href="https://www.sciencedirect.com/science/article/pii/S0223523422004007?via%3Dihub" target="_blank" >https://www.sciencedirect.com/science/article/pii/S0223523422004007?via%3Dihub</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1016/j.ejmech.2022.114498" target="_blank" >10.1016/j.ejmech.2022.114498</a>
Alternative languages
Result language
angličtina
Original language name
Contemporary mTOR inhibitor scaffolds to diseases breakdown: A patent review (2015–2021)
Original language description
Mechanistic target of rapamycin (mTOR) is a highly conserved protein kinase acting as a central regulator of cell functions. The kinase forms two distinct mTOR complexes termed as mTORC1 and mTORC2. Dysregulation of mTOR activity is associated with various pathological conditions. Inhibition of overactivated mTOR represent a rational approach in the treatment of numerous human diseases. Rapamycin is a potent natural inhibitor of mTOR exhibiting significant antitumor and immunosuppressive activity. Derivatization of rapamycin provided rapalogs, the first generation of mTOR inhibitors that selectively inhibit mTORC1 activity. Further interest of research community resulted in creation of the second generation of mTOR inhibitors involving both, mTOR kinase inhibitors and dual phosphoinositide 3-kinase (PI3K)/mTOR inhibitors. Recently, combining advances of first and second generation of mTOR inhibitors yielded in the third generation of inhibitors termed as rapalinks. Nowadays, novel inhibitors belonging to all of the three generations are still under development. These inhibitors help us better to understand role of mTOR in mTOR signaling pathway as well as in diverse human diseases. In this review, we summarize recent reported mTOR inhibitors or methods of use thereof in the treatment of various diseases. © 2022 Elsevier Masson SAS
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30107 - Medicinal chemistry
Result continuities
Project
<a href="/en/project/GA20-22037S" target="_blank" >GA20-22037S: The therapeutic potential of novel mTOR inhibitors within the process of ageing</a><br>
Continuities
P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)
Others
Publication year
2022
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
European Journal of Medicinal Chemistry
ISSN
0223-5234
e-ISSN
1768-3254
Volume of the periodical
238
Issue of the periodical within the volume
August
Country of publishing house
FR - FRANCE
Number of pages
29
Pages from-to
"Article number: 114498"
UT code for WoS article
000810543200004
EID of the result in the Scopus database
2-s2.0-85131533377